Does defibrotide prophylaxis decrease the risk of acute graft versus host disease following allogeneic hematopoietic...

Area of Science:

• Hematology
• Transplantation immunology
• Pharmacology

Background:

• Veno-occlusive disease (VOD) prophylaxis with defibrotide (DF) may mitigate acute graft-versus-host disease (aGvHD) by preventing tissue damage.
• Understanding the impact of DF timing on aGvHD development is crucial for optimizing patient outcomes post-hematopoietic cell transplant (HCT).

Purpose of the Study:

• To investigate the role of DF prophylaxis in reducing the incidence and severity of aGvHD at 180 days post-allogeneic HCT.
• To compare the effects of post-HCT versus pre-HCT DF administration on aGvHD development.

Main Methods:

• Retrospective evaluation of 195 adult patients undergoing allogeneic HCT.
• Patients were categorized into three groups: no DF, DF administered post-HCT (days 1-14), and DF administered pre-HCT (concurrent with conditioning).
• Incidence and severity of aGvHD were assessed at day 180 post-HCT.

Main Results:

• The overall aGvHD rate at D+180 was 46.5% (no DF), 40% (DF/post-HCT), and 25.5% (DF/pre-HCT).
• Rates of grades III/IV aGvHD were 15.5% (no DF), 11.2% (DF/post-HCT), and 0% (DF/pre-HCT).
• A trend towards decreased aGvHD incidence and severity was observed with DF use, particularly when administered pre-HCT concurrently with conditioning (p=0.057 for total aGvHD, p=0.051 for grades III/IV).

Conclusions:

• Defibrotide prophylaxis may play a role in decreasing the incidence and severity of aGvHD following allogeneic HCT.
• Administering DF concurrently with the conditioning regimen appears to be the most effective strategy for preventing severe aGvHD.